|
PIK3CB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6116000000066E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.595850E-04 |
| Normal-vs-Stage2 |
1.535820E-03 |
| Normal-vs-Stage3 |
1.64619999964977E-07 |
| Normal-vs-Stage4 |
1.63609999992431E-08 |
| Stage1-vs-Stage2 |
7.359000E-01 |
| Stage1-vs-Stage3 |
4.196000E-02 |
| Stage1-vs-Stage4 |
5.343100E-03 |
| Stage2-vs-Stage3 |
2.843800E-01 |
| Stage2-vs-Stage4 |
5.479800E-02 |
| Stage3-vs-Stage4 |
2.088200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.17949999995015E-07 |
| Normal-vs-AfricanAmerican |
1.391780E-01 |
| Normal-vs-Asian |
1.50901999999009E-05 |
| Caucasian-vs-AfricanAmerican |
6.482300E-02 |
| Caucasian-vs-Asian |
5.818200E-01 |
| AfricanAmerican-vs-Asian |
4.560200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.80980000167253E-08 |
| Normal-vs-Female |
3.76859999999812E-05 |
| Male-vs-Female |
4.680500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.080030E-03 |
| Normal-vs-Age(41-60Yrs) |
3.95870000002851E-07 |
| Normal-vs-Age(61-80Yrs) |
1.07129999982192E-07 |
| Normal-vs-Age(81-100Yrs) |
2.323600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.141600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.680300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.231000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.105200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.879400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.972400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.682100E-02 |
| Classical-VS-Follicular |
6.669000E-01 |
| Classical-VS-Other |
1.946810E-01 |
| Classical-VS-Normal |
1.66932999999814E-05 |
| Tall-VS-Follicular |
3.782500E-02 |
| Tall-VS-Other |
7.212800E-01 |
| Tall-VS-Normal |
1.75989999995352E-06 |
| Follicular-VS-Other |
2.476600E-01 |
| Follicular-VS-Normal |
1.856330E-03 |
| Other-VS-Normal |
2.479600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.08369999999958E-05 |
| Normal-vs-N1 |
2.08779999999464E-06 |
| N0-vs-N1 |
1.159190E-01 |
|
|
